News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
40 Under 40
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
40 Under 40
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
324,601 Results
Type
Article (26366)
Company Profile (146)
Press Release (298089)
Multimedia
Podcasts (30)
Webinars (11)
Section
Business (91366)
Career Advice (1309)
Deals (14168)
Drug Delivery (80)
Drug Development (38320)
Employer Resources (155)
FDA (7994)
Job Trends (8559)
News (153467)
Policy (13472)
Tag
Academia (1971)
Academic (2)
Accelerated approval (3)
Adcomms (17)
Allergies (75)
Alliances (25247)
ALS (68)
Alzheimer's disease (853)
Antibody-drug conjugate (ADC) (70)
Approvals (8029)
Artificial intelligence (174)
Autoimmune disease (13)
Automation (12)
Bankruptcy (97)
Best Places to Work (7327)
BIOSECURE Act (13)
Biosimilars (66)
Biotechnology (90)
Bladder cancer (56)
Brain cancer (17)
Breast cancer (157)
Cancer (1195)
Cardiovascular disease (104)
Career advice (1154)
Career pathing (33)
CAR-T (89)
Cell therapy (256)
Cervical cancer (12)
Clinical research (31271)
Collaboration (530)
Compensation (202)
Complete response letters (12)
COVID-19 (1323)
CRISPR (29)
C-suite (172)
Cystic fibrosis (81)
Data (1383)
Decentralized trials (1)
Denatured (21)
Depression (29)
Diabetes (162)
Diagnostics (3357)
Digital health (7)
Diversity (7)
Diversity, equity & inclusion (39)
Drug discovery (72)
Drug pricing (61)
Drug shortages (5)
Duchenne muscular dystrophy (62)
Earnings (26535)
Editorial (17)
Employer branding (24)
Employer resources (134)
Events (49216)
Executive appointments (518)
FDA (8820)
Friedreich's ataxia (2)
Frontotemporal dementia (4)
Funding (498)
Gene editing (68)
Generative AI (16)
Gene therapy (214)
GLP-1 (392)
Government (2290)
Grass and pollen (2)
Guidances (36)
Healthcare (9850)
Huntington's disease (15)
IgA nephropathy (20)
Immunology and inflammation (49)
Indications (16)
Infectious disease (1409)
Inflammatory bowel disease (104)
Inflation Reduction Act (8)
Influenza (26)
Intellectual property (51)
Interviews (196)
IPO (6380)
IRA (23)
Job creations (1568)
Job search strategy (1006)
Kidney cancer (2)
Labor market (35)
Layoffs (188)
Leadership (16)
Legal (2171)
Liver cancer (42)
Lung cancer (166)
Lymphoma (92)
Machine learning (3)
Management (52)
Manufacturing (174)
MASH (27)
Medical device (6291)
Medtech (6295)
Mergers & acquisitions (8154)
Metabolic disorders (375)
Multiple sclerosis (50)
NASH (11)
Neurodegenerative disease (45)
Neuropsychiatric disorders (7)
Neuroscience (1207)
NextGen: Class of 2025 (3664)
Non-profit (3456)
Now hiring (38)
Obesity (189)
Opinion (129)
Ovarian cancer (43)
Pain (55)
Pancreatic cancer (39)
Parkinson's disease (100)
Partnered (14)
Patents (106)
Patient recruitment (65)
Peanut (42)
People (33632)
Pharmaceutical (41)
Pharmacy benefit managers (4)
Phase I (9023)
Phase II (13488)
Phase III (11599)
Pipeline (665)
Policy (70)
Postmarket research (1238)
Preclinical (3956)
Press Release (61)
Prostate cancer (61)
Psychedelics (18)
Radiopharmaceuticals (120)
Rare diseases (276)
Real estate (3199)
Recruiting (59)
Regulatory (10181)
Reports (42)
Research institute (1728)
Resumes & cover letters (165)
Rett syndrome (5)
RNA editing (2)
RSV (32)
Schizophrenia (47)
Series A (93)
Series B (55)
Service/supplier (8)
Sickle cell disease (39)
Special edition (8)
Spinal muscular atrophy (108)
Sponsored (24)
Startups (2368)
State (1)
Stomach cancer (8)
Supply chain (29)
Tariffs (9)
The Weekly (9)
Vaccines (322)
Venture capitalists (31)
Weight loss (117)
Women's health (15)
Worklife (18)
Date
Today (8)
Last 7 days (504)
Last 30 days (1436)
Last 365 days (18662)
2025 (6224)
2024 (20046)
2023 (22460)
2022 (27552)
2021 (30632)
2020 (28324)
2019 (25198)
2018 (18731)
2017 (16363)
2016 (15825)
2015 (17415)
2014 (12650)
2013 (10239)
2012 (10756)
2011 (11091)
2010 (10054)
Location
Africa (477)
Alabama (29)
Alaska (7)
Arizona (100)
Arkansas (9)
Asia (18680)
Australia (3392)
California (3413)
Canada (1012)
China (244)
Colorado (135)
Connecticut (173)
Delaware (112)
Europe (46499)
Florida (541)
Georgia (135)
Hawaii (1)
Idaho (23)
Illinois (281)
India (22)
Indiana (254)
Iowa (8)
Japan (132)
Kansas (46)
Kentucky (15)
Louisiana (8)
Maine (14)
Maryland (459)
Massachusetts (2611)
Michigan (127)
Minnesota (205)
Mississippi (2)
Missouri (45)
Montana (17)
Nebraska (10)
Nevada (41)
New Hampshire (18)
New Jersey (1087)
New Mexico (19)
New York (1020)
North Carolina (632)
North Dakota (8)
Northern California (1519)
Ohio (128)
Oklahoma (7)
Oregon (22)
Pennsylvania (731)
Puerto Rico (9)
Rhode Island (16)
South America (627)
South Carolina (9)
Southern California (1239)
Tennessee (43)
Texas (429)
United States (12994)
Utah (81)
Virginia (72)
Washington D.C. (42)
Washington State (235)
West Virginia (1)
Wisconsin (47)
324,601 Results for "kezar life sciences".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Press Releases
Kezar Life Sciences to Present Topline Results from the PORTOLA Phase 2a Trial Evaluating Zetomipzomib for the Treatment of Patients with Autoimmune Hepatitis on March 25, 2025
March 24, 2025
·
6 min read
Biotech Bay
Kezar Life Sciences to Participate in the Jefferies Global Healthcare Conference
Kezar Life Sciences, Inc. (Nasdaq: KZR) today announced that Chris Kirk, Co-founder and Chief Executive Officer, will participate in a fireside chat at the Jefferies Global Healthcare Conference on Wednesday, June 5, 2024, at 12:30 pm ET in New York, NY.
May 29, 2024
·
1 min read
Drug Development
Kezar Cuts Lupus Program After Patient Deaths, Focuses on Autoimmune Hepatitis
Earlier this month, Kezar Life Sciences announced that the mid-stage test of zetomipzomib in lupus nephritis had been placed on an FDA clinical hold. Now, that program is being terminated.
October 17, 2024
·
2 min read
·
Annalee Armstrong
Press Releases
Kezar Life Sciences Announces Positive Topline Results from the PORTOLA Phase 2a Trial Evaluating Zetomipzomib for the Treatment of Patients with Autoimmune Hepatitis (AIH) and Reports Fourth Quarter and Year End 2024 Financial Results
March 26, 2025
·
15 min read
FDA
Kezar’s Autoimmune Drug Hit With Second FDA Clinical Hold in as Many Months
Following patient deaths in a lupus trial that led to the termination of that program, Kezar’s autoimmune candidate zetomipzomib faces a partial clinical hold barring four trial participants from continuing treatment in the open-label portion of the trial, though the trial itself will continue as planned.
November 13, 2024
·
2 min read
·
Heather McKenzie
M&A
Concentra Spies New Target After Kezar’s Lupus Trial Hold
After four patient deaths, Kezar’s lupus trial is officially on hold, sparking investor Kevin Tang’s interest for acquisition.
October 9, 2024
·
1 min read
·
Kate Goodwin
Business
Kezar Life Sciences Reports First Quarter 2024 Financial Results and Provides Business Update
Kezar Life Sciences, Inc., a clinical-stage biotechnology company developing novel small molecule therapeutics to treat unmet needs in immune-mediated diseases and cancer, reported financial results for the first quarter ended March 31, 2024 and provided a business update.
May 9, 2024
·
8 min read
Business
New Jersey’s Life Sciences Scene Continues Expanding Beyond Big Pharma
Known as the home of big-name companies including Johnson & Johnson, New Jersey has become a destination for more and more small and midsize life sciences businesses. Choose New Jersey, Grace Therapeutics and Onyx Equities executives discuss the state’s life sciences scene.
April 10, 2025
·
6 min read
·
Angela Gabriel
Immunology and inflammation
Kezar Reports Four Patient Deaths in Mid-Stage Lupus Nephritis Study, Pauses Enrollment
William Blair analyst Matt Phipps in a note to investors wrote that despite the patient deaths, the totality of the data still leans in favor of Kezar Life Sciences’ investigational immunoproteasome inhibitor zetomipzomib.
October 1, 2024
·
2 min read
·
Tristan Manalac
Press Releases
Kezar Life Sciences to Present at Virtual KOL Event Hosted by William Blair on Zetomipzomib Clinical Development in Autoimmune Hepatitis and Provide a Safety Update from the PALIZADE Trial for Lupus Nephritis on February 27, 2025
February 18, 2025
·
6 min read
1 of 32,461
Next
